Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
mRNA-1010 demonstrated superior relative vaccine efficacy
Extended lab space for product development, customer demos, and training
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Star Health Insurance is modernising its claims ecosystem to be future-ready
The inspection concluded with zero Form 483 observations
Changhua site meets international regulatory standards for global medical applications
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
